INTRODUCTION {#SEC1}
============

In recent decades, non-coding RNA (ncRNA) has gradually become a research hotspot because of its important roles in a wide range of biological processes. ncRNA can interact with various macromolecules, including DNA, RNA and proteins, and regulate gene expression at transcriptional, post-transcriptional and epigenetic levels ([@B1],[@B2]). The number of identified ncRNAs has also sharply increased with the widespread usage of high-throughput technology in different cells and tissues. The latest GENCODE version 29 annotated more than 40 000 ncRNAs in the human genome. Many ncRNAs are important oncogenes or tumour suppressor genes, such as *HULC* ([@B3]) and *HOXB-AS3* ([@B4]). However, compared with protein-coding genes, the function of most ncRNAs remains to be deciphered.

Single-nucleotide polymorphisms (SNPs), the most common type of human genetic variation, play important roles in human complex traits and diseases ([@B5]). Genome-wide association studies (GWAS) have found extensive SNPs associated with various traits and diseases. However, most GWAS-detected risk SNPs are located in the genomic non-coding regions ([@B8]), which indicates that ncRNAs may be possible causal targets of some GWAS loci ([@B9]). For example, rs6983267 on human chromosome 8q24.21 is a potential genetic biomarker of colorectal cancer predisposition and is located far from protein-coding genes. Recent studies demonstrated that rs6983267 may exert its role through influencing the expression of lncRNA *CCAT2* ([@B10],[@B11]). Therefore, investigation of the effects of SNPs on ncRNA expression will help to understand how risk alleles contribute towards tumorigenesis and cancer development.

Expression quantitative trait locus (eQTL) analysis links variations in gene expression to genotypes and has been considered a powerful tool to understand the effects and molecular mechanism of functional SNPs ([@B12]). However, most eQTL analyses are focused on the associations between genotypes and protein-coding genes; only a few ncRNA-related eQTL (ncRNA-eQTL) analyses have been performed at the genome-wide level ([@B16]). In recent years, although some ncRNA-related SNP databases such as LincSNP 2.0 ([@B17]), MSDD ([@B18]) and lncRNASNP2 ([@B19]) have been developed to explore the relationship of ncRNAs and SNPs, no database has been developed to specifically and comprehensively quantify the association between SNP and ncRNA expression. The Cancer Genome Atlas (TCGA) consortium ([@B20]) has generated DNA germline genotype datasets, transcriptome profiling and patient survival data for over 10 000 primary tumours in 33 cancer types. Using these valuable datasets, we previously performed eQTL analyses for all cancer types and developed the pancanQTL online database ([@B21]), which provides eQTLs of 20 531 genes. However, most of the genes in pancanQTL are protein-coding genes. Recently, the TCGA database has updated its gene expression profiles and provided expression profiles of more than 40 000 lncRNAs. In addition, the TCGA has also provided microRNA (miRNA) expression profiles. These data enable us to systematically analyse associations between SNPs and the gene expression of ncRNAs (including lncRNAs and miRNAs). Thus, in this study, using TCGA genotype data and the latest expression profiles, we developed a computational pipeline to systematically identify ncRNA-eQTLs across 33 cancer types. In addition, we linked ncRNA-eQTLs to known GWAS loci and patient survival times and identified thousands of GWAS-related eQTLs and survival-related eQTLs. Finally, we constructed a user-friendly database, ncRNA-eQTL (<http://ibi.hzau.edu.cn/ncRNA-eQTL>), for users to browse and download data.

DATA COLLECTION AND PROCESSING {#SEC2}
==============================

Collection and processing of genotype data {#SEC2-1}
------------------------------------------

Genotype data of 33 cancer types (full names of cancer types are shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}) of each individual were obtained from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>), which were called by the Affymetrix SNP 6.0 array platform and included 898 620 SNPs (Figure [1A](#F1){ref-type="fig"}). To increase the power for eQTL discovery, we imputed autosomal variants for all samples using IMPUTE2 ([@B22]) in each cancer type, with 1000 Genomes Phase 3 as the reference panel ([@B23]). A two-step imputation procedure was used to improve the computation efficiency. TCGA genotype data were first pre-phased to certain haplotypes and then imputed from the reference panel into the estimated study haplotypes. After imputation, the following criteria ([@B24]) were employed to remove SNPs: (i) imputation confidence score, INFO \< 0.4, (ii) minor allele frequency (MAF) \< 5%, (iii) SNP missing rate \> 5% for best-guessed genotypes at posterior probability ≥ 0.9 and (iv) Hardy--Weinberg equilibrium *P*-value \< 1 × 10^−6^ estimated by Hardy--Weinberg R package ([@B25]) (Figure [1B](#F1){ref-type="fig"}).

![Flowchart of the ncRNA-eQTL database. (**A**) Data collection of sequencing, genotype and GWAS data. (**B**) Processing of sequencing and gene expression data. (**C**) Database content of four types of eQTLs (cis-eQTLs, trans-eQTLs, survival-eQTLs, GWAS-eQTLs).](gkz711fig1){#F1}

Expression data processing and covariates {#SEC2-2}
-----------------------------------------

Gene expression profiles generated from RNA sequencing (RNA-seq) and small RNA sequencing (smRNA-seq) for each sample were obtained from the TCGA data portal (<https://gdc-portal.nci.nih.gov/>). The gene annotation, which was used for TCGA RNA-seq and miRNA-seq annotation, was downloaded from the GENCODE (version 22) website (<https://www.gencodegenes.org/>) and miRBase (<http://www.mirbase.org/>). According to the annotation, we removed all the protein-coding genes from the profiles. In each cancer type, lncRNAs with an average expression of ≥ 0.01 FPKM and miRNAs with an average expression of ≥0.01 TPM were retained. To minimize the effect of outliers on the regression scores, the expression values for each gene across all samples were transformed into a standard normal based on rank ([@B24]) (Figure [1B](#F1){ref-type="fig"}).

Global expression data may be influenced by several factors, such as batch effects ([@B26]) and genetic and non-genetic biases ([@B27]). Thus, covariates are often included to correct known and unknown confounders and increase the sensitivity of eQTL analyses ([@B24]). To adjust the global effect of population structure, we first used smartpca in the EIGENSOFT program ([@B28]) to perform principal component analysis (PCA) for each cancer type. The top five principal components in the genotype data were selected as covariates. To eliminate the possible batch effects and other confusions hidden in the expression data, we used PEER software ([@B29]) to select the first 15 PEER factors from the expression data as covariates. Other factors, such as tumour stage ([@B30]), gender ([@B24]) and age ([@B12]), were also counted as additional covariates (Figure [1A](#F1){ref-type="fig"}).

Identification of cis- and Trans-eQTL using Matrix eQTL {#SEC2-3}
-------------------------------------------------------

Cis-eQTL and trans-eQTL analyses were performed in our study. The cis-eQTLs were defined if the SNP was within 1 Mb from the gene transcriptional start site (TSS) and regulating the corresponding gene expression ([@B24]), and trans-eQTLs were defined if the eQTL was beyond that region or on another chromosome. To perform cis-eQTL analyses and trans-eQTL analyses, we first downloaded SNP annotations (GRCh38) (<https://www.ncbi.nlm.nih.gov/projects/SNP>) from the dbSNP database. We analysed the associations between each ncRNA and autosomal SNP through linear regression by employing a computationally efficient eQTL analysis called Matrix eQTL ([@B31]), controlling for population bias, sex, age, tumour stage and unobserved factors in the expression data for each cancer type ([@B29],[@B31]). We defined eQTLs as SNPs with false discovery rates (FDRs) calculated by MatrixEQTL \< 0.05 (Figure [1C](#F1){ref-type="fig"}).

Identification of GWAS-associated eQTLs {#SEC2-4}
---------------------------------------

Overlaps between ncRNA-eQTLs and SNPs in GWAS regions were identified to explore the possible target genes of existing GWAS loci. To achieve that, we first downloaded all the known risk tag SNPs identified by GWAS from the National Human Genome Research Institute (NHGRI) GWAS Catalog ([@B32]) (<http://www.ebi.ac.uk/gwas>, accessed September 2018), a collection of data from GWAS for various human diseases and traits. Then, we obtained the SNPs in linkage disequilibrium (LD) with these tag SNPs from SNAP ([@B33]) (<https://personal.broadinstitute.org/plin/snap/ldsearch.php>). The parameters were set as follows: SNP dataset: 1000 Genomes; *r*^2^ (the square of the Pearson correlation coefficient of linkage disequilibrium) threshold: 0.5; population panel: CEU (Utah residents with northern and western European ancestry); distance limit: 500 kb. Finally, these GWAS tag SNPs and LD SNPs were mapped to ncRNA-eQTL results.

Identification of survival-associated eQTLs {#SEC2-5}
-------------------------------------------

To prioritize promising ncRNA-eQTLs, we identified ncRNA-eQTLs that may be associated with patient survival times. The clinical data, including patient overall survival times, were downloaded from the TCGA data portal. For each ncRNA-eQTL, we divided the samples into three different groups: AA (homozygous genotype), Aa (heterozygous genotype) and aa (homozygous genotype), and removed the group with samples fewer than three for reliable survival analysis and Kaplan--Meier (KM) *P*-value calculation. Then, the differences in survival times between the groups were detected by log-rank test, and KM curves were introduced to visualize the survival time difference of each group. In addition, survival-associated eQTLs were confirmed for ncRNA-eQTLs that fulfilled the condition of FDR \< 0.05.

Database construction {#SEC2-6}
---------------------

We organized all results in MySQL (version 5.6) relation tables and constructed a web interface using HTML, CSS and PHP (version 5.4) running on an Apache web server (version 2.4.6). A highly flexible and editable plug-in for the jQuery JavaScript library called DataTables (<https://datatables.net/>) was integrated to display the data content in a dynamic way.

DATABASE CONTENT AND THE WEB INTERFACE {#SEC3}
======================================

Database content and statistics of lncRNA-related eQTLs {#SEC3-1}
-------------------------------------------------------

Using genotype data and RNA-seq data, we first performed lncRNA-related cis-eQTL and trans-eQTL association analyses in each of the 33 cancer types independently. The sample sizes of cancer types ranged from 36 in cholangiocarcinoma (CHOL) to 1067 in breast invasive carcinoma (BRCA), with a median of 177 (Table [1](#tbl1){ref-type="table"}). After genotype imputation, the incorporated SNPs ranged from 2 745 615 in BRCA to 5 078 753 in acute myeloid leukaemia (LAML), with a median of 4 525 414. There were 40 670 ncRNAs in the expression profiles of each cancer type. We filtered the ncRNAs with expression \>0.01 FPKM, resulting in a median of 12 554 ncRNAs included in the analyses. All SNPs within the $\documentclass[12pt]{minimal}
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###### 

The summary of samples and lncRNA related eQTLs in this study

                                      Cis         Trans                                   
  ------- ------ -------- ----------- ----------- -------- ----------- --------- -------- ---------
  ACC     77     10 673   3 567 953   6906        229      6547        1030      49       934
  BLCA    403    12 090   4 191 159   205 824     4077     156 228     29 840    935      23 714
  BRCA    1067   13 170   2 745 615   498 969     8124     308 016     62 764    2 328    46 137
  CESC    242    12 410   4 276 554   101 968     2626     82 242      20 779    735      17 555
  CHOL    36     12 217   4 012 151   0           0        0           0         0        0
  COAD    282    11 063   4 505 758   169 256     3558     129 931     25 618    859      20 423
  DLBC    47     11 447   4 819 767   122         8        121         82        4        82
  ESCA    148    19 921   4 431 385   44 450      1238     37 484      6177      218      4723
  GBM     139    15 247   4 525 414   74 593      1743     61 211      6109      202      5518
  HNSC    492    11 768   4 249 925   294 234     4698     217 470     38 283    1 075    31 312
  KICH    65     11 736   3 755 519   9 289       265      8 075       382       26       320
  KIRC    520    14 537   4 578 071   558 380     7216     380 619     57 962    1 492    47 020
  KIRP    287    12 554   4 881 400   228 243     4350     175 762     28 242    905      22 640
  LAML    96     19 856   5 078 753   44 537      1069     34 233      5570      148      4802
  LGG     498    14 213   4 626 469   723 868     7844     465 249     71 517    1 595    54 899
  LIHC    367    9691     4 157 271   171 255     3333     128 444     22 425    764      17 725
  LUAD    506    13 624   4 384 017   347 537     5714     249 589     39 040    1 130    31 147
  LUSC    495    14 319   3 745 439   321 036     5556     226 779     44 235    1 236    38 111
  MESO    81     12 393   4 759 523   15 045      372      14 140      2152      97       1779
  OV      251    16 660   2 966 217   102 136     3423     79 467      11 534    515      9317
  PAAD    177    13 298   4 991 769   139 332     2623     112 129     16 561    494      13 926
  PCPG    174    11 971   4 709 166   119 083     2571     93 599      16 630    552      14 066
  PRAD    478    12 945   4 822 300   604 359     7181     412 073     69 412    1 686    56 307
  READ    91     11 298   4 540 674   18 312      539      16 750      4645      153      4138
  SARC    257    11 454   4 087 361   105 751     2607     85 278      17 121    600      14 261
  SKCM    103    11 315   4 854 570   14 150      427      13 014      4856      159      4501
  STAD    371    19 117   4 300 207   175 519     3637     128 258     21 276    635      15 847
  TGCT    148    14 304   4 811 363   95 579      1989     79 971      11 477    325      9839
  THCA    495    12 874   4 876 701   702 674     7426     464 482     57 645    1 353    44 077
  THYM    119    13 223   4 930 920   92 773      1907     74 540      9355      330      7028
  UCEC    173    11 548   4 957 767   44 594      1327     38 605      9933      411      8385
  UCS     55     13 439   3 871 537   51          5        51          0         0        0
  UVM     77     9182     4 692 767   15 620      405      14 530      3300      128      2993
  Total   8817   26 839   7 169 904   6 045 445   98 087   4 294 887   715 952   21 139   573 526

We identified a total of 6 045 445 eQTL-lncRNA pairs in 33 cancer types of cis-eQTL analyses at a per-tissue FDR of \< 0.05, which corresponded to a median *P*-value = 5.28 × 10^−6^. No cis-eQTL or trans-eQTL were identified in CHOL because of the low sample size of 36. Among other cancer types, the number of cis-eQTLs ranged from 51 in uterine carcinosarcoma (UCS) to 465 249 in lower grade glioma (LGG). GTEx multi-tissue eQTL studies have reported a directly proportional relationship of egenes (genes associated with eQTLs) with sample size, and no plateauing has been reported at a maximum 300 sample size ([@B24],[@B34]). In our study, we also observed that the number of cis-eQTLs was significantly positively correlated with the sample size, even after adjusted numbers of genotype and ncRNAs (*P*-value = 6.12 × 10^−8^, *R*~s~ = 0.79, [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}), and a similar trend was exhibited for egenes (*P*-value = 8.66 × 10^−10^, *R*~s~ = 0.85, [Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}).

The distribution of cis-eQTLs relative to the transcription start site shows that the majority of eQTLs are approximately symmetrically centred around the TSS ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}), with 90% within ±300 kb of the TSS. Overall, 80.2% of lncRNA-eQTLs only regulate the expression of one lncRNA, and 19.8% of lncRNA-eQTLs can regulate the expression of more than two genes ([Supplementary Figure S1D](#sup1){ref-type="supplementary-material"}).

Across all cancer types, we identified a total of 715 952 eQTL--lncRNA pairs in trans-eQTL analyses at per-tissue FDR of \<0.05, which corresponded to a median *P*-value = 3.45 × 10^−13^. The number of trans-eQTLs/egenes was also significantly positively correlated with the sample size (*P*-value = 5.52 × 10^−9^, *R* = 0.83 for eQTLs, *P*-value = 2.38 × 10^−11^, *R* = 0.88 for egenes, [Supplementary Figure S1E and F](#sup1){ref-type="supplementary-material"}).

Data summary of miRNA-related eQTLs {#SEC3-2}
-----------------------------------

Using genotype data and miRNA-seq data, we further performed analyses of miRNA-related eQTLs (miRNA-eQTLs) across 33 cancer types. In the cis-eQTL analysis, we identified a total of 87 833 eQTL--miRNA pairs at a per-tissue FDR \< 0.05, and the number of pairs ranged from six in lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) to 11 779 in THCA ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). There was only one cis-regulated miRNA in UCS and DLBC, while 301 egenes were identified in THCA. For trans-eQTL analysis, a total of 5170 eQTL--miRNA pairs were identified, and the number of trans-eQTLs ranged from two in adrenocortical carcinoma (ACC) to 658 in lung squamous cell carcinoma (LUSC). The number of miRNA-related cis-eQTLs and trans-eQTLs was also significantly correlated with the number of samples (*P*-value = 1.41 × 10^−7^, *R* = 0.79 for cis and *P*-value = 7.75 × 10^−5^, *R* = 0.69 for trans, respectively).

Case study of eQTLs associated with patient survival times and GWAS loci {#SEC3-3}
------------------------------------------------------------------------

To prioritize promising ncRNA-eQTLs, we linked our eQTLs with TCGA patients' clinical data and identified eQTLs that may be associated with overall survival times. We identified a total of 8235 lncRNA-eQTLs and 116 miRNA-eQTLs associated with patient overall survival times across 33 cancer types at FDR \< 0.05. For example, rs10965295 and rs3131997 were significantly associated with patient overall survival times in LGG (Figure [2A](#F2){ref-type="fig"}), and these two SNPs could regulate CDK*N2B-AS1* expression and hsa-miR-5699-5p in LGG, respectively (Figure [2B](#F2){ref-type="fig"}). These survival-eQTLs and related ncRNAs may play important roles in cancer development and could serve as predictive and prognostic biomarkers.

![Case study of eQTLs in survival-eQTLs and GWAS-eQTLs. (**A**) nc-eQTL rs10965295 and rs3131997 affect patient overall survival times in LGG. (**B**) egene CDKN2B-AS1 of rs10965295 and egene hsa-miR-5699--5p of rs3131997 were significantly differentially expressed among genotypes in LGG. (**C**) nc-eQTL rs17191861 located in BRCA GWAS locus. (**D**) egene *LINC01235* of rs17191861 was significantly differentially expressed in paired tumour and normal samples.](gkz711fig2){#F2}

To explore ncRNA-eQTLs and possible causal genes in known GWAS loci, we identified overlaps between ncRNA-eQTLs and SNPs in GWAS regions. A total of 45 826 tag SNPs were downloaded from the GWAS Catalog; 920 379 SNPs in LD with these tag SNPs were obtained, and all these SNPs were defined as GWAS SNPs. By mapping ncRNA-eQTLs to GWAS SNPs, we identified 253 080 lncRNA-eQTLs and 9252 miRNA-eQTLs overlapping with known disease/traits associated loci. To provide an example of a GWAS-eQTL application, we further mapped BRCA ncRNA-eQTL results to GWAS SNPs of corresponding breast cancer. Among breast GWAS SNPs, we found a total of 1989 eQTLs, which could regulate the expression of 161 ncRNAs. We further analysed the expression of these ncRNAs in tumours and their matched normal samples and found that several ncRNAs were significantly differentially expressed between paired tumour and normal samples at FDR \< 0.05. These ncRNAs could be possible causal targets of BRCA GWAS loci. For example, Michailidou *et al.* found that rs77457752 on chromosome 9p23 is significantly associated with breast cancer risk (*P*-value = 8 × 10^−7^), but they did not report its possible target genes ([@B35]). rs77457752 is located in the intron of the lncRNA *LINC00583*. We retrieved the expression level of *LINC00583* and found that it is not expressed in 91% of breast cancer samples. In the upstream and downstream regions of rs77457752, there are only a few genes (Figure [2C](#F2){ref-type="fig"}), and we did not find any correlated protein-coding genes of rs77457752 and its LD SNPs. In our results, we found that rs17191861, which is in LD with rs77457752 (LD *r^2^* = 0.73), is significantly correlated with *LINC01235*. Differential expression analysis shows that the expression of *LINC01235* in tumours is significantly lower than that of adjacent normal samples (*P*-value \< 2 × 10^−16^, fold change = -2.44, Figure [2D](#F2){ref-type="fig"}), suggesting that *LINC01235* may be a potential causal gene in this risk locus.

Web interface {#SEC3-4}
-------------

To facilitate broad access to these ncRNA-eQTLs and associated data, we developed a user-friendly data portal, ncRNA-eQTL (<http://ibi.hzau.edu.cn/ncRNA-eQTL/index.php>) (Figure [3A](#F3){ref-type="fig"}), which includes two sub-databases, lncRNA-eQTL home and miRNA-eQTL home. The two sub-databases can be switched from the button on the top right of our data portal. Each sub-database provides four major datasets: cis-eQTLs, trans-eQTLs, survival-eQTLs and GWAS-eQTLs (Figure [3B](#F3){ref-type="fig"}). On the homepage, we designed a quick search option in which users can input their interested SNPs or genes. Then, four dynamic tables displaying cis-eQTLs, trans-eQTLs, survival-eQTLs and GWAS-eQTLs with related information will be presented (Figure [3C](#F3){ref-type="fig"}). The cis-eQTL and trans-eQTL table display SNP ID, SNP genomic position, SNP alleles, ncRNA, ncRNA position, β-value (effect size of SNP on gene expression), *r*-value (correlation coefficient between SNP and expression) and *P*-value of eQTLs. For each record, a vector diagram of a boxplot is provided to display the association between SNP genotypes and gene expression. The survival-eQTL table displays SNP ID, SNP genomic position, SNP alleles, log-rank test *P*-value and median survival times of different genotypes. For each record, a vector diagram of the Kaplan--Meier plot is embedded to display the association between SNP genotypes and overall survival times. The GWAS-eQTLs table will return the SNP information, gene information and related GWAS traits.

![Web interface of the ncRNA-eQTL database. (**A**) ncRNA-eQTL database header with navigation bar. (**B**) Four different searching modules we offer. (**C**) The results of a quick search. (**D**) Heat map of cis-eQTLs across 33 cancer types. The colour of each box indicates the values of the correlation coefficient (*r*). (**E**) Heat map of trans-eQTLs across 33 cancer types.](gkz711fig3){#F3}

We also designed a 'Pancan-eQTL' page, where users can submit a batch of SNPs and/or gene symbols. Then, two interactive heat maps of cis-eQTL (Figure [3D](#F3){ref-type="fig"}) and trans-eQTL (Figure [3E](#F3){ref-type="fig"}) will display all the values of the correlation coefficient (*r*). Users can download all four datasets for each cancer type from the 'Download' section. The 'Help' page provides information for data collection, processing and result summary. ncRNA-eQTL welcomes any feedback by email to the address provided in the 'Contact' page. We have tested the database on various web browsers, including Chrome (recommended), Firefox, Opera, Windows Edge and Safari of macOS.

DISCUSSION {#SEC4}
==========

In summary, ncRNA-eQTL is a comprehensive ncRNA (lncRNA and miRNA)-related eQTL resource that uses large cancer samples to evaluate the effects of genetic variants on ncRNA expression. It comprises cis/trans-eQTLs, survival-eQTLs and GWAS-eQTLs and provides a user-friendly interface for users to query, browse and download data of interest. To the best of our knowledge, this is the first database specifically identifying ncRNA-eQTLs in multiple cancer types. In addition, we observed that the number of eQTLs increased with the sample size. The sample sizes of most of the other eQTL studies were below 300 ([@B30],[@B36]), but in our analyses, 12 cancer types had more than 300 samples, indicating that the ncRNA-eQTL database would be the most comprehensive resource for ncRNA-eQTLs.

Two important features of our resource are linking ncRNA-eQTLs to patient survival times and known GWAS loci, which will help users narrow down their candidate eQTLs and egenes. Many researchers have been looking for genetic biomarkers related to disease susceptibility, development and prognosis and have committed to analysing the biological mechanisms behind genetic determinations. In our study, we found that thousands of genetic variants could influence cancer prognosis and provided their related non-coding egenes. By integrating ncRNA-eQTL data with known GWAS data, we identified thousands of ncRNA-eQTLs in known GWAS regions. ncRNAs and related genetic determinations are still poorly functionally characterized. These survival and GWAS-related ncRNA-eQTLs and egenes could be important candidates for further experimental validation. Our database will facilitate the fine mapping of post-GWAS and identification of therapeutic biomarkers for cancer. We believe that this valuable resource will be of significant interest to the research community, especially in the field of ncRNA and cancer-related studies.

Supplementary Material
======================

###### 

Click here for additional data file.

We thank all members in Zhang lab for helping in paper writing and website construction. Server support from the Hubei Key Laboratory of Agricultural Bioinformatics is also appreciated.

SUPPLEMENTARY DATA {#SEC5}
==================

[Supplementary Data](https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkz711#supplementary-data) are available at NAR Online.

FUNDING {#SEC6}
=======

Huazhong Agricultural University Scientific & Technological Self-innovation Foundation \[11041810351 to J.G., W.Z\]. Funding for open access charge: Huazhong Agricultural University Scientific & Technological Self-innovation Foundation \[11041810351\].

*Conflict of interest statement*. None declared.
